ARIAD Pharmaceuticals Inc. (ARIA) announced updated clinical results on its investigational tyrosine kinase inhibitor, AP26113, in patients with advanced non-small cell lung cancer from an ongoing Phase 1/2 trial.
The study confirmed compelling clinical evidence of the anti-tumor activity of AP26113 at multiple dose levels in patients with anaplastic lymphoma kinase positive non-small cell lung cancer, including brain metastases, and initial clinical evidence of anti-tumor activity in patients with epidermal growth factor receptor mutant non-small cell lung cancer.
The study identified a recommended Phase 2 dose of 180 mg administered orally once daily. The Phase 2 portion of the trial has opened and enrolling patients at this dose in the first four expansion cohorts, the company noted.
Further Phase 1 evaluation of the 240 mg dose is continuing in non-small cell lung cancer patients with documented epidermal growth factor receptor mutant and the secondary mutation, T790M, following disease progression on prior epidermal growth factor receptor tyrosine kinase inhibitor therapy, the company added.
For comments and feedback: editorial@rttnews.com